Catalyst
Slingshot members are tracking this event:
The final survival analysis for custirsen in combination with docetaxel as second-line chemotherapy in approximately 700 patients with non-small cell lung cancer is expected in the first half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| OGXI | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 08, 2017
Occurred Source:
https://www.ncbi.nlm.nih.gov/pubmed/28283282
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Custirsen, Docetaxel
